Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 501–600 of 1,001
Tumour‐specific CD4 T cells eradicate melanoma via indirect recognition of tumour‐derived antigen
Shklovskaya, E., Terry, A. M., Guy, T. V., Buckley, A., Bolton, H. A., Zhu, E., Holst, J., & Groth, B. F. D. S. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.14 · Cited by 37
Evaluation of machine learning methods to predict peptide binding to MHC Class I proteinsPreprint
Bhattacharya, R., Sivakumar, A., Tokheim, C. J., Guthrie, V. B., Anagnostou, V., Velculescu, V. E., & Karchin, R. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/154757 · Cited by 37
“These strategies will become intractable as the field expands to the important problem of handling MHC Class II alleles [32], which bind peptides of highly variable lengths.”
BackgroundMuquith, M., Espinoza, M., Elliott, A., Xiu, J., Seeber, A., El‐Deiry, W. S., Antonarakis, E. S., Graff, S. L., Hall, M. J., Borghaei, H., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00752-x · Cited by 40
“Thus, a fundamental requirement for effective cancer immunotherapies is the recognition of tumor neoantigens by immune cells to drive de novo or amplify existing T cell responses 9–11 .”
Grandi, A., Fantappiè, L., Irene, C., Valensin, S., Tomasi, M., Stupia, S., Corbellari, R., Caproni, E., Zanella, I., Isaac, S. J., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00481 · Cited by 39
“Synthetic peptides (20 μg each) corresponding to neoepitopes M03, M20, M26, M27, and M68 (23) were mixed with 20 μg of “empty” OMVs and after challenging mice with 2 × 105 tumor cells the mixture was used to immunize mice every 3 days for a total of 7 injections (Figure 5A).”
BackgroundMethodInfluentialNam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100093 · Cited by 38
Amateur antigen‐presenting cells in the tumor microenvironment
Darragh, L. B., & Karam, S. D. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23354 · Cited by 38
Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022) · Vaccines · doi:10.3390/vaccines10020196 · Cited by 40
“Historically, there have been several limiting factors in neoantigen research, particularly with respect to the methods to identify effective neoantigens and, as a result, very few processes to identify viable therapeutic neoantigen targets existed previously [5,6].”
BackgroundA nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA
Carson, C. S., Becker, K. W., Garland, K. M., Pagendarm, H. M., Stone, P. T., Arora, K., Wang-Bishop, L., Baljon, J. J., Cruz, L. D., Joyce, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.020 · Cited by 37
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
Mohsen, M. O., Speiser, D. E., Michaux, J., Pak, H., Stevenson, B. J., Vogel, M. T., Inchakalody, V. P., de Brot, S., Dermime, S., Coukos, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002927 · Cited by 37
“To explore whether the induced immune response is mediated by a single NeoAG or the multiple ones, mice were vaccinated with Q β (1668)- NeoAG L -1 or Q β (1668)- NeoAG L -2 or Q β (1668)- NeoAG L -3 or Q β (1668)- NeoAG L -4 separately or with the multitarget vaccine Q β (1668)- NeoAG L .”
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 40
Hoecke, L. V., Riederer, S., Saelens, X., Sutter, G., & Rojas, J. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1802968 · Cited by 35
“By ELISPOT, we determined the T cell response directed against the major histocompatibility complex (MHC) class II-restricted neo-epitope B16M30 or its wild-type counterpart B16-WT30.(17) VACV expressing MLKL performed better than their control counterparts, showing pronounced reactivity against the neo-epitope but no…”
BackgroundMethodInfluentialHernandez, R., LaPorte, K. M., Hsiung, S., Savio, A. S., & Malek, T. R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002865 · Cited by 39
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 38
Jing, Z., Wang, S., Xu, K., Tang, Q., Li, W., Zheng, W., Shi, H., Su, K., Liu, Y., & Hong, Z. (2022) · Advanced Science · doi:10.1002/advs.202201496 · Cited by 38
LNK suppresses interferon signaling in melanoma
Ding, L., Sun, Q., Edwards, J. J., Fernández, L. T., Ran, X., Zhou, S., Scolyer, R. A., Wilmott, J. S., Thompson, J. F., Doan, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09711-y · Cited by 36
Nongenic cancer-risk SNPs affect oncogenes, tumour-suppressor genes, and immune function
Fagny, M., Platig, J., Kuijjer, M. L., Lin, X., & Quackenbush, J. F. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0614-3 · Cited by 37
Moradi, A., Pourseif, M. M., Jafari, B., Parvizpour, S., & Omidi, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104790 · Cited by 37
Tumor neoantigens: Novel strategies for application of cancer immunotherapy
Guan, H., Wu, Y., Li, L., Yang, Y., Qiu, S., Zhao, Z., Chu, X., He, J., Chen, Z., ZHANG, Y., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029924 · Cited by 37
“[44] rapidly screened and synthesized a multi-epitope neoantigen mRNA vaccine, which elicited an evident T cell immune response, based on the mutation level of exon sequencing and the ability to bind to MHC-II.”
Lowenstein, P. R., & Castro, M. G. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.07.006 · Cited by 35
“A capacity to recognize tumor neo-antigens is a central determinant of the power of immune rejection of tumors (Kreiter et al., 2015; Linnemann et al., 2015; Yadav et al., 2014).”
Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration
Ziller, A., Nogueira, S. S., Huehn, E., Funari, S. S., Brezesinski, G., Hartmann, H., Şahin, U., Haas, H., & Langguth, P. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01022 · Cited by 34
Oh, M. S., Abascal, J. W., Rennels, A. K., Salehi‐Rad, R., Dubinett, S. M., & Liu, B. (2025) · Cancers · doi:10.3390/cancers17061027 · Cited by 37
“Vaccines composed of tumor neoantigen peptides have been investigated in murine models and have demonstrated the ability to elicit durable neoantigen-specific T cell responses [170–172].”
Aptamers: A New Technological Platform in Cancer Immunotherapy
Pastor, F. (2016) · Pharmaceuticals · doi:10.3390/ph9040064 · Cited by 33
New challenges in therapeutic vaccines against HIV infection
Leal, L., Lucero, C., Gatell, J. M., Gallart, T., Plana, M., & García, F. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322513 · Cited by 37
“personalized mRNA [128], peptide [124], or dendritic cell [129]”
BackgroundNovel tools to assist neoepitope targeting in personalized cancer immunotherapy
Saini, S. K., Rekers, N. H., & Hadrup, S. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx544 · Cited by 34
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Mensali, N., Grenov, A., Pati, N. B., Dillard, P., Myhre, M. R., Gaudernack, G., Kvalheim, G., Inderberg, E. M., Bakke, O., & Wälchli, S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1558663 · Cited by 36
“However, several studies have shown that CD4 Helper T cells play a critical role in the promotion and maintenance of memory CD8 T cells, and also in tumor control,(6) suggesting that both CD8 and CD4 T cell responses should be evoked through vaccination strategies.(6,7) Consequently, in order to obtain efficient stimu…”
ResultKines, R. C., Thompson, C. D., Spring, S. M., Li, Z., Pinos, E. D. L., Monks, S. A., & Schiller, J. T. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0974 · Cited by 33
“Researchers have demonstrated the utility of these “neoantigens” in cancer immunotherapy (11-14), and their identification and targeting has been at the forefront of current tumor immunotherapeutic discovery.”
BackgroundVaccine-Based Immunotherapy for Head and Neck Cancers
Beyaert, S. P., Machiels, J., & Schmitz, S. (2021) · Cancers · doi:10.3390/cancers13236041 · Cited by 34
“This suggested that personalized vaccines can be made using algorithms that select mutations from a patient’s mutanome that have the highest probability of creating widely expressed tumor antigens to induce a CD4+ response [45,49].”
BackgroundLaheurte, C., Galaine, J., Beziaud, L., Dosset, M., Kerzerho, J., Jacquemard, C., Gaugler, B., Ferrand, C., Dormoy, A., Aubin, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1137416 · Cited by 34
“In addition, the immunization with CD4C T immunogenic neo-epitopes confers strong antitumor response.(20) This observation underlines the critical role of CD4C T cells immunity in cancer immunosurveillance.”
BackgroundNext Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
Melanoma vaccines: clinical status and immune endpoints
Maurer, D. M., Butterfield, L. H., & Vujanovic, L. N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000535 · Cited by 37
Jiang, T., Su, C., Cheng, R., Pan, Y., Zhang, H., He, J., He, Y., Tang, R., Ren, S., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.03 · Cited by 36
“In a syngeneic mouse model, using vaccine with a computationally designed synthetic mRNA generated by syngeneic tumor, a complete rejection of established tumors along with potent CD4+ and CD8+ T cell responses were observed (12).”
MethodHiLive: real-time mapping of illumina reads while sequencing
Lindner, M. S., Strauch, B., Schulze, J. M., Tausch, S. H., Dąbrowski, P. W., Nitsche, A., & Renard, B. Y. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw659 · Cited by 32
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 34
Moran, A. E., Polesso, F., & Weinberg, A. D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502659 · Cited by 34
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
Ascierto, M. L., Melero, I., & Ascierto, P. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00152 · Cited by 31
“However, the necessary biotechnology and bioinformatics for epitope prediction and individualized vaccine production are only at their infancy to consider wide scale deployment (55, 56).”
BackgroundKarasaki, T., Nagayama, K., Kawashima, M., Hiyama, N., Murayama, T., Kuwano, H., Nitadori, J., Anraku, M., Sato, M., Miyai, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.006 · Cited by 34
Mellman, I., Hubbard-Lucey, V. M., Tontonoz, M. J., Kalos, M. D., Chen, D. S., Allison, J. P., Drake, C. G., Levitsky, H., Lonberg, N., van der Burg, S. H., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0045 · Cited by 31
“In addition, the identification of new T-cell epitopes utilizing various bioinformatics tools and prediction algorithms can enable the identification of T cells that are reactive to these epitopes for further functional testing of their target cell killing in vitro (58).”
Ritz, D., Sani, E., Dêbiec, H., Ronco, P. M., Neri, D., & Fugmann, T. (2018) · PROTEOMICS · doi:10.1002/pmic.201700246 · Cited by 33
Zeiner, P. S., Zinke, J., Kowalewski, D. J., Bernatz, S., Tichy, J., Ronellenfitsch, M. W., Thorsen, F., Berger, A., Forster, M.-T., Müller, A., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0521-5 · Cited by 34
“Tumor cell-derived (neo)-antigens are presented by the ubiquitously expressed HLA class I molecules, although recent data demonstrates murine mutant epitopes also on major histocompatibility complex (MHC) class II molecules [22].”
BackgroundUeda, N., Uemura, Y., Zhang, R., Kitayama, S., Iriguchi, S., Kawai, Y., Yasui, Y., Tatsumi, M., Ueda, T., Liu, T., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.04.025 · Cited by 31
“Tumor antigen-specific CD4 T helper (Th) cells can induce a wide range of tumor antigen-specific cytotoxic T lymphocyte (CTL) responses via the maturation of dendritic cells (DCs), which avoid tumor evasion because of a mutation in a single target epitope (Kreiter et al., 2015).”
BackgroundFacing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 32
“Neoantigens presented on HLA class II was found to promote recognition of tumor epitopes and antitumor activity as well as presentation on HLA class I [36,66].”
BackgroundThe Ways of Isolating Neoantigen-Specific T Cells
Li, Q., & Ding, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01347 · Cited by 32
“Vaccination with neo-peptides has been shown to prime CD4+ and CD8+ T-cell responses in mouse models (54, 84).”
BackgroundForster, S., & Radpour, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569017 · Cited by 33
“Although tumor-individual and patient-specific Ags, so-called neoantigens, have been known for a long time, they can only be exploited by highthroughput screening/sequencing methods including the help of dedicated software and bioinformatic algorithms to predict the peptide binding avidity to MHC molecules (28).”
MethodMaine, C. J., Richard, G., Spasova, D. S., Miyake-Stoner, S. J., Sparks, J., Moise, L., Sullivan, R. P., Garijo, O., Choz, M., Crouse, J. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.027 · Cited by 33
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved
Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 32
“Although typically focused on CD8 + T-cell epitopes, the importance and critical role of CD4 + T-cell epitopes has also emerged from preclinical studies (13,16), whether directly or indirectly cytolytic (17,18) or to provide critical help to CD8 + T cells (19).”
BackgroundRole of CD4+CD25+FOXP3+TRegcells on tumor immunity
Hariyanto, A. D., Permata, T. B. M., & Gondhowiardjo, S. A. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1975228 · Cited by 36
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 33
“II-restricted antigens in immunotherapies (102–104) and mutated neoantigens that stimulate anti-tumour CD4 T cell responses have recently been identified in other syngeneic tumour models (103, 105, 106).”
BackgroundVerdegaal, E. M. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.004 · Cited by 33
“Similarly, Ag-spreading is postulated to mediate the clinical efficacy of MHC class II neoepitope vaccination in several mouse models [16].”
BackgroundLi, F., Chen, C., Ju, T., Gao, J., Yan, J., Wang, P., Xu, Q., Hwu, P., Du, X., & Lizee, G. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238539 · Cited by 31
“cytotoxic T lymphocyte (CTL) responses in human melanoma patients, and similar approaches in murine models have resulted in substantial tumor regressions.(13-14) These highly encouraging studies have led to the initiation of several mutated peptide vaccine trials aiming to test whether such clinical benefits are trans…”
BackgroundWalters, J. N., Ferraro, B., Duperret, E. K., Kraynyak, K. A., Chu, J. S., Saint-Fleur, A., Yan, J., Levitsky, H., Khan, A. S., Sardesai, N. Y., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.022 · Cited by 33
“These neo-antigens are patient specific, and CD4 T cells can respond to these mutated epitopes to elicit tumor regression.(34,35) Furthermore, adoptive transfer of tumor-infiltrating T lymphocytes (TILs) and successful checkpoint blockade cancer immunotherapy are both thought to elicit tumor rejection that is mediated…”
BackgroundIdentification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
Iiizumi, S., Ohtake, J., Murakami, N., Kouro, T., Kawahara, M., Isoda, F., Hamana, H., Kishi, H., Nakamura, N., & Sasada, T. (2019) · Cancers · doi:10.3390/cancers11020266 · Cited by 33
“For example, in murine tumor models, vaccination with MHC class II-restricted neoepitopes could induce strong anti-tumor activity [14].”
BackgroundResultKeshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 31
Tan, Z., Liu, L., Chiu, M. S., Cheung, K., Yan, C. W., Yu, Z., Lee, B. K., Liu, W., Man, K., & Chen, Z. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1518672 · Cited by 30
“The peptide gp70-AH1 is a well-characterized immunodominant CTL epitope derived from glycoprotein 70 (gp70) of endogenous murine leukemia virus.(21,22) The TWIST1 is a transcription factor that is crucial to the tumor metastatic process and tumor resistance to drug treatment.”
BackgroundNeoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 31
Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
McCann, K. J., Witzleben, A. V., Thomas, J., Wang, C., Wood, O., Singh, D. K., Boukas, K., Bendjama, K., Silvestre, N., Nielsen, F. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003821 · Cited by 36
“15 The expression of MHC Class II by tumor cells could afford the potential for direct recognition and engagement of tumor cells presenting tumor antigens to CD4 + helper T cells.”
Self-citationmRNA vaccination in breast cancer: current progress and future direction
Jiang, X., & Liu, Q. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04805-z · Cited by 35
“injection of LNPs encapsulated mRNA vaccines ensures systemic distribution specifically in APCs, particularly significant DCs, with protection from degradation and optimization of bioavailability (Kreiter et al. 2015).”
BackgroundThe biogenesis of the immunopeptidome
Admon, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101766 · Cited by 32
The European Regulatory Environment of RNA-Based Vaccines
Hinz, T., Kallen, K., Britten, C. M., Flamion, B., Granzer, U., Hoos, A., Huber, C., Khleif, S. N., Kreiter, S., Rammensee, H., et al. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_13 · Cited by 32
Self-citationChemical Derivatization Strategy for Extending the Identification of MHC Class I Immunopeptides
Chen, R., Fauteux, F., Foote, S., Stupak, J., Tremblay, T., Gurnani, K., Fulton, K. M., Weeratna, R. D., Twine, S. M., & Li, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02420 · Cited by 30
Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells
Schluck, M., Hammink, R., Figdor, C. G., Verdoes, M., & Weiden, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00931 · Cited by 34
“Furthermore, a RNA vaccination study clearly showed the importance of CD4 T cell neo-epitopes in controlling murine tumors (11).”
BackgroundNielsen, J. S., Sedgwick, C. G., Shahid, A., Zong, Z., Brumme, Z. L., Yu, S., Liu, L. Y., Kroeger, D. R., Treon, S. P., Connors, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2023 · Cited by 30
“This conclusion is supported by murine studies, where vaccination with mutant peptides can prime CD4þ and CD8þ T-cell responses to approximately 30% of selected mutations (41, 42).”
BackgroundResultHutzler, S., Erbar, S., Jabulowsky, R. A., Hanauer, J. R. H., Schnotz, J. H., Beißert, T., Bodmer, B. S., Eberle, R., Böller, K., Klamp, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16928-8 · Cited by 29
Liu, S., Yang, Y., Jiang, C., Quan, Q., Xie, Q., Wang, X., He, W., Rong, Y., Chen, P., Yang, Q., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1570-z · Cited by 29
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
Dyugay, I. A., Lukyanov, D. K., Turchaninova, M. A., Serebrovskaya, E. O., Bryushkova, E. A., Zaretsky, A. R., Khalmurzaev, O., Matveev, V. B., Shugay, M., Shelyakin, P. V., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0489 · Cited by 40
“Multiple studies have demonstrated substantial involvement of CD4þ T cells (66, 67), NK cells (68), and B cells (1–5) in cancer immunosurveillance and immunotherapy responses (1, 2).”
BackgroundHe, R., Yuan, X., Chen, Z., & Zheng, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109444 · Cited by 31
Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles
Caproni, E., Corbellari, R., Tomasi, M., Isaac, S. J., Tamburini, S., Zanella, I., Grigolato, M., Gagliardi, A., Benedet, M., Baraldi, C., et al. (2023) · Cancers · doi:10.3390/cancers15133328 · Cited by 29
“[20], elicited epitopespecific T cells when injected s.”
BackgroundInfluentialHarnessing enucleated cancer cells as Trojan horse cell vaccines
Fang, W., Jing, Z., Li, Y., Zhang, Z., Lin, Z., Yang, Z., Tian, Y., Zhang, C., Ma, Y., Hou, L., et al. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101752 · Cited by 38
A novelin silicoframework to improve MHC-I epitopes and break the tolerance to melanoma
Capasso, C., Magarkar, A., Cervera-Carrascón, V., Fusciello, M., Feola, S., Müller, M. J., Garofalo, M., Kuryk, Ł., Tähtinen, S., Pastore, L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1319028 · Cited by 29
“In fact, the presence of amino acid changes in proteins of malignant cells can create epitopes that are able to drive antitumor responses.(15) Chen et al.”
BackgroundVaccine-based immunotherapy and related preclinical models for glioma
Yao, L., Hatami, M., Ma, W., & Skutella, T. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.009 · Cited by 30
Stem-like CD8+ T cells in cancer
Steiner, C., Denlinger, N., Huang, X., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426418 · Cited by 30
Harbige, J., Eichmann, M., & Peakman, M. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.08.001 · Cited by 28
“CD8+ T cells associated with tumour 337 regression following checkpoint blockade cancer immunotherapy target mutation-produced 338 neo-epitopes [63] and such neo-epitopes have also proved to be effective therapeutic 339 vaccines for melanoma [64].”
BackgroundZhao, T., Cheng, L., Zang, T., & Hu, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01191 · Cited by 28
“Many scholars try to find personalized treatment for melanoma and other cancers through major histocompatibility complex (MHC) (Kreiter et al., 2015; Bentzen et al., 2016; Johnson et al., 2016).”
BackgroundDexamethasone premedication suppresses vaccine-induced immune responses against cancer
Vormehr, M., Lehar, S. M., Kranz, L. M., Tähtinen, S., Oei, Y. A., Javinal, V., Delamarre, L., Walzer, K. C., Diken, M., Kreiter, S., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1758004 · Cited by 30
“Enzyme-linked ImmunoSpot assays detecting IFNγ release of MC38-specific T cells were performed as previously described.(32) -3h +3h 0d -3h +3h 7d 5d 12d 28d 35d 21d”
MethodSelf-citationCD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages
Haabeth, O. A. W., Hennig, K., Fauskanger, M., Løset, G. Å., Bogen, B., & Tveita, A. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001434 · Cited by 28
Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 30
“While the focus of anti-tumor immunity research has long been on MHC I and CD8 T cells, it has been shown in mouse models that the majority of immunogenic mutations are presented via MHC II and recognized by CD4 T cells [103].”
BackgroundIsser, A., Silver, A. B., Pruitt, H. C., Mass, M., Elias, E. H., Aihara, G., Kang, S.-S., Bachmann, N., Chen, Y., Leonard, E. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33597-y · Cited by 28
Longino, N. V., Yang, J., Iyer, J. G., Ibrani, D., Chow, I., Laing, K. J., Campbell, V. L., Paulson, K. G., Kulikauskas, R. M., Church, C. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0103 · Cited by 30
“Therapeutic cancer vaccines primarily targeting CD4þ T cells can induce epitope spreading of CD8þ T-cell responses (19) and have shown promise in treating melanoma (20, 21).”
BackgroundLi, Q., Zeng, H., Liu, T., Wang, P., Zhang, R., Zhao, B., Feng, T., Yang, Y., Wu, J., Zheng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54650-y · Cited by 33
Neoepitopes-based vaccines: challenges and perspectives
Alcazer, V., Bonaventura, P., Tonon, L., Valsesia‐Wittmann, S., Caux, C., & Depil, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.011 · Cited by 30
Naciūtė, M., Niemi, V., Kemp, R. A., & Hook, S. M. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.04.020 · Cited by 27
Personal Neoantigen Vaccines for the Treatment of Cancer
Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 30
NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice
McVey, J. C., Green, B. L., Ruf, B., McCallen, J., Wabitsch, S., Subramanyam, V., Diggs, L. P., Heinrich, B., Greten, T. F., & Ma, C. (2022) · iScience · doi:10.1016/j.isci.2022.103847 · Cited by 28
“As highlighted by previous papers, CD4+ T cells can play an important role in anti-tumor immunity (Alspach et al., 2019; Borst et al., 2018; Kreiter et al., 2015).”
Puth, S., Verma, V., Hong, S. H., Tan, W., Lee, S. E., & Rhee, J. H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121542 · Cited by 29
Liu, Q., Wang, L., Lin, H., Wang, Z., Wu, J. S., Guo, J., Wen, S., Ran, L., Yue, Z., Su, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875718 · Cited by 28
“Studies of neoantigens have identified a peculiar phenomenon whereby peptides selected in silico for their ability to bind MHC class I largely yield CD4 T-cell responses in vivo (51), potentially supporting the practical feasibility of CD4 T-cell adoptive transfer therapy.”
BackgroundShi, Y., Liu, Y., Huang, J., Luo, Z., Guo, X., Jiang, M., Li, X., Lu, Y., Liu, X., Shan, X., et al. (2022) · Theranostics · doi:10.7150/thno.71760 · Cited by 29
“A major limitation of current protein- or mRNAbased standalone vaccine strategies is the lack of a multifaceted and coordinated mobilization of the MHC system, which usually leads to a failure in generating compelling anti-tumor clinical effects [32, 33].”
BackgroundHuang, L., Zhang, J., Wei, B., Chen, S., Zhu, S., Qi, W., Pei, X., Li, L., Liu, W., Wang, Y., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.003 · Cited by 29
Li, R., Hao, Y., Roche, K. C., Chen, G., Pan, W., Wang, A. Z., & Min, Y. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122290 · Cited by 28
Tumor antigens in human cancer control
Kelderman, S., & Kvistborg, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.004 · Cited by 29
Zolkind, P., Dunn, G. P., Lin, T., Griffith, M., Griffith, O. L., & Uppaluri, R. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.09.010 · Cited by 28
A clinically applicable adjuvant for an atherosclerosis vaccine in mice
Kobiyama, K., Vassallo, M., Mitzi, J., Winkels, H., Pei, H., Kimura, T., Miller, J. F., Wolf, D., & Ley, K. F. (2018) · European Journal of Immunology · doi:10.1002/eji.201847584 · Cited by 28
Functionally specialized human CD4+ T-cell subsets express physicochemically distinct TCRs
Kasatskaya, S. A., Ladell, K., Egorov, E. S., Miners, K. L., Davydov, A. N., Metsger, M., Staroverov, D. B., Matveyshina, E. K., Shagina, I. A., Mamedov, I. Z., et al. (2020) · eLife · doi:10.7554/elife.57063 · Cited by 32
Du, F., & Liu, Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24141 · Cited by 28
Eisenberg, V., Shamalov, K., Meir, S., Hoogi, S., Sarkar, R., Pinker, S., Markel, G., Porgador, A., & Cohen, C. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01212 · Cited by 28
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Lione, L., Salvatori, E., Petrazzuolo, A., Massacci, A., Maggio, R., Conforti, A., Compagnone, M., Aurisicchio, L., Ciliberto, G., & Palombo, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1898832 · Cited by 27
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 27
Salomon, N., Selmi, A., Grunwitz, C. R., Kong, A. H., Stanganello, E., Neumaier, J., Petschenka, J., Diken, M., Kreiter, S., Türeci, Ö., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03134-9 · Cited by 27
Self-citationLee, S., Jang, G.-Y., Lee, J., Park, S. H., Han, H. D., Park, Y., & Kang, T. H. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03220-6 · Cited by 26
“Neoantigen vaccines have been in the spotlight because they are personalized treatments that analyze the genome of cancer cells derived from cancer patients and can be treated efficiently[12, 31].”
BackgroundMethodUehara, J., Ohkuri, T., Kosaka, A., Ishibashi, K., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.072 · Cited by 29
Ouyang, Z., Gao, Y., Yang, R., Shen, M., & Shi, X. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01571 · Cited by 26
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.